Ashurst Advises MedinCell S.A. on Approximately €48 Million Private Placement

"Ashurst advised MedinCell S.A. on a private placement raising approximately €48 million from international institutional investors. The placement—led by Jefferies, Evercore, Leerink Partners and Oddo BHF as bookrunners—involved the issue of 2,370,000 new ordinary shares at €20.35 per share, with participation from health-focused investors including Perceptive Advisors, Kurma Growth Opportunities, Affinity Asset Advisors and Polar Capital alongside existing major shareholders. Proceeds will fund additional clinical/partnering programs, enhance future collaboration economics (favoring downstream royalties), advance MedinCell’s proprietary long‑acting injectable (LAI) platform including next‑generation LAI technologies, and support general corporate purposes. The new shares were admitted to trading on Euronext Paris. Ashurst’s deal team was led by François Hellot, with Alexandra Ber (Paris) and Rodrigo Romero Hidalgo (London)."